The Code of Federal Regulations of the United States of AmericaU.S. Government Printing Office, 1992 The Code of Federal Regulations is the codification of the general and permanent rules published in the Federal Register by the executive departments and agencies of the Federal Government. |
No grāmatas satura
1.–5. rezultāts no 100.
i. lappuse
... Federal Register 21 PARTS 300 TO 499 Revised as of April 1 , 1992 CONTAINING A CODIFICATION OF DOCUMENTS OF GENERAL APPLICABILITY AND FUTURE EFFECT AS OF APRIL 1 , 1992 TFA LCO PB t . 21 Sec . 300.50 PART 300 - GENERAL Subpart A- [.
... Federal Register 21 PARTS 300 TO 499 Revised as of April 1 , 1992 CONTAINING A CODIFICATION OF DOCUMENTS OF GENERAL APPLICABILITY AND FUTURE EFFECT AS OF APRIL 1 , 1992 TFA LCO PB t . 21 Sec . 300.50 PART 300 - GENERAL Subpart A- [.
5. lappuse
... Subpart A- [ Reserved ] Subpart B - Combination Drugs Fixed - combination drugs for humans . prescription Subpart C - Substances Generally Prohibited From Drugs 300.100 Chlorofluorocarbon propellants . Subpart A- [ Reserved ] Subpart B ...
... Subpart A- [ Reserved ] Subpart B - Combination Drugs Fixed - combination drugs for humans . prescription Subpart C - Substances Generally Prohibited From Drugs 300.100 Chlorofluorocarbon propellants . Subpart A- [ Reserved ] Subpart B ...
6. lappuse
Sec . Subpart C - New Drugs Exempted From Prescription - Dispensing Requirements 310.200 Prescription - exemption procedure . 310.201 Exemption for certain drugs limit- ed by new drug applications to prescrip- tion sale . Subpart D ...
Sec . Subpart C - New Drugs Exempted From Prescription - Dispensing Requirements 310.200 Prescription - exemption procedure . 310.201 Exemption for certain drugs limit- ed by new drug applications to prescrip- tion sale . Subpart D ...
62. lappuse
... Subpart A - General Provisions Scope . 312.2 Applicability . 312.3 Definitions and interpretations . 312.6 Labeling of an investigational new drug . 312.7 Promotion and charging for investi- gational drugs . 312.10 Waivers . Subpart B ...
... Subpart A - General Provisions Scope . 312.2 Applicability . 312.3 Definitions and interpretations . 312.6 Labeling of an investigational new drug . 312.7 Promotion and charging for investi- gational drugs . 312.10 Waivers . Subpart B ...
63. lappuse
... Subpart E - Drugs Intended to Treat Life- threatening and Severely - debilitating III- nesses 312.80 Purpose . 312.81 Scope . 312.82 Early consultation . 312.83 Treatment protocols . 312.84 Risk - benefit analysis in review of marketing ...
... Subpart E - Drugs Intended to Treat Life- threatening and Severely - debilitating III- nesses 312.80 Purpose . 312.81 Scope . 312.82 Early consultation . 312.83 Treatment protocols . 312.84 Risk - benefit analysis in review of marketing ...
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
300 milligrams accurately weighed acid active ingredients addition to complying agar diffusion assay amdinocillin amended ampicillin azlocillin batch for potency Calculate cefotiam cefpiramide ceftazidime ceftriaxone cefuroxime chapter chromatograph clavulanic acid crystallinity cyclacillin described in paragraph dicloxacillin dilute to volume Dissolve distilled water dosage forms drug product Food and Drug Further dilute gentamicin hetacillin hydrochloride immediate containers injection labeled in accordance less than 90 loss on drying lution master standard means a specific methods of assay-(1 micrograms milligrams milliliter milliliter estimated mobile phase monohydrate nafcillin neomycin neomycin sulfate number of milligrams oxacillin peak penicillin ples polymyxin potassium phosphate preparing the sample Proceed as directed products containing pyrogens reagent represented to contain request shall contain Requests for certification Requirements for certification Results of tests sample solution sodium solu standard solution Standards of identity stock solution Subpart tablets tests and assays Tests and methods tests except sterility ticarcillin tion volumetric flask
Populāri fragmenti
94. lappuse - The responsibility for the human subject must always rest with a medically qualified person and never rest on the subject of the research, even though the subject has given his or her consent.
135. lappuse - As used in this subsection and subsection (e), the term "substantial evidence" means evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be, concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended,...
95. lappuse - The refusal of the patient to participate in a study must never interfere with the physician-patient relationship. 5. If the physician considers it essential not to obtain informed consent, the specific reasons for this proposal should be stated in the experimental protocol for transmission to the independent committee (I, 2). 6. The physician can combine medical research with professional care, the objective being the acquisition of new medical knowledge, only to the extent that medical research...
125. lappuse - Secretary when the application was approved, shows that such drug is not shown to be safe for use under the conditions of use upon the basis of which the application was approved...
125. lappuse - ... drug are inadequate to assure and preserve its identity, strength, quality, and purity and were not made adequate within a reasonable time after receipt of written notice from the...
286. lappuse - ... of the act if shipped or sold to, or in the possession of, persons regularly and lawfully engaged in instruction in pharmacy, chemistry, or medicine not involving clinical use; or in law enforcement; or in research not involving clinical use; or in chemical analysis or physical testing, provided they are to be used only for such instruction, law enforcement, research, analysis, or testing, and provided further that their labels bear the statement "Not for drug use.
95. lappuse - In any medical study, every patient — including those of a control group, if any — should be assured of the best proven diagnostic and therapeutic method.
234. lappuse - If offered for use in arthritis or rheumatism, in juxtaposition therewith, the statement: Caution— If pain persists for more than 10 days, or redness is present, or in conditions affecting children under 12 years of age, consult a physician immediately.
94. lappuse - Because it is essential that the results of laboratory experiments be applied to human beings to further scientific knowledge and to help suffering humanity...
134. lappuse - A person who requests a hearing may not rely upon allegations or denials but is required to set forth specific facts showing that there is a genuine and substantial issue of fact that requires a hearing with respect to a particular drug product specified in the request for hearing. (i) Where a specific notice of opportunity for hearing (as defined in paragraph (b)(l) of this section) is used, the Commissioner will enter summary judgment against a person who requests a hearing, making findings and...